A major breakthrough came in 2023, when, for the first time, the tracer [18F]ACI-12589 finally demonstrated that (i) a-synuclein pathology can be visualized by PET and that (ii) the PET signal can differentiate MSA cases from controls and other neurodegenerative cases [9]. This evidence concerns the gene SNCA and multiple system atrophy.